• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Ipilimumab for Early-Stage Melanoma?

Article

Despite promising results, experts believe it's too early to use ipilimumab for early-stage melanoma, high toxicity being one of the limiting factors.

The drug is

for use in stage IV disease.

For the first time, ipilimumab (Yervoy, Bristol-Myers Squibb) has been shown to be effective in an adjuvant setting for earlier-stage melanoma. already approved

Results presented here at the 2014 Annual Meeting of the American Society of Clinical Oncology® show that ipilimumab significantly delayed recurrence, compared with placebo, in these stage III patients.

In a new study, known as EORTC 18071, more than 900 patients with stage III disease received ipilimumab (10 mg/kg) at a dose higher than the dose approved (3 mg/kg) for stage IV disease.

But experts say that these results are not strong enough to catapult the immunotherapy into the role of an important treatment option in this setting. And they cite the drug's toxicity as an ongoing concern, given the marginal benefit shown so far.

Read the original report here:

http://bit.ly/1i1OFWY

Source: Medscape

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.